Complementary Drug Therapy

  • Sergio Canavero
  • Vincenzo Bonicalzi


Inflammation has been linked to chronic pain, including peripheral neuropathic pain. CCP is often associated with root injury, i.e., PNP: this triggers local inflammation and supraspinal changes in cytokine or chemokine expression (neuroinflammation) [1]. Since inflammation has been associated, among many others, with depression, aggressively targeting supraspinal pro-inflammatory mediators at critical time points in appropriate clinical populations is likely to be a novel avenue to treat debilitating affective disturbances in neuropathic conditions [2].


  1. 1.
    Bjurstrom MF, Giron SE, Griffis CA. Cerebrospinal fluid cytokines and neurotrophic factors in human chronic pain populations: a comprehensive review. Pain Pract. 2016;16(2):183–203.CrossRefPubMedGoogle Scholar
  2. 2.
    Fiore NT, Austin PJ. Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation? Brain Behav Immun. 2016;56:397–411.CrossRefPubMedGoogle Scholar
  3. 3.
    Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R. Effect of vitamin D supplementation on pain: a systematic review and meta-analysis. Pain Physician. 2016;19:415–27.PubMedGoogle Scholar
  4. 4.
    Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. J Steroid Biochem Mol Biol. 2017 (in press).Google Scholar
  5. 5.
    Allison DJ, Thomas A, Beaudry K, Ditor DS. Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial. J Neuroinflammation. 2016;13:152.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Andresen SR, Bing J, Hansen RM, Biering-Sørensen F, Johannesen IL, Hagen EM, Rice AS, Nielsen JF, Bach FW, Finnerup NB. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain. 2016;157:2097–103.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sergio Canavero
    • 1
  • Vincenzo Bonicalzi
    • 2
  1. 1.HEAVEN/GEMINI International Collaborative GroupTurinItaly
  2. 2.AOUCittà della Salute e della Scienza di Torino, Department of Neurosciences, Rita Levi MontalciniUniversità di TorinoTurinItaly

Personalised recommendations